Metformin inhibits β-catenin phosphorylation on Ser-552 through an AMPK/PI3K/Akt pathway in colorectal cancer cells.

Int J Biochem Cell Biol

Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de Buenos Aires, Argentina; Instituto de Inmunología, Genética y Metabolismo, Facultad de Farmacia y Bioquímica, Hospital de Clínicas "José de San Martín", Caba, 1120, Argentina. Electronic address:

Published: July 2019

Several epidemiologic studies have revealed strong inverse associations between metformin use and risk of colorectal cancer development. Nevertheless, the underlying mechanisms are still uncertain. The Wnt/β-catenin pathway, which plays a central role in intestinal homeostasis and sporadic colorectal cancer development, is regulated by phosphorylation cascades that are dependent and independent of Wnt. Here we report that a non-canonical Ser phosphorylation in β-catenin, which promotes its nuclear accumulation and transcriptional activity, is blocked by metformin via AMPK-mediated PI3K/Akt signaling inhibition.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biocel.2019.05.004DOI Listing

Publication Analysis

Top Keywords

colorectal cancer
12
cancer development
8
metformin inhibits
4
inhibits β-catenin
4
β-catenin phosphorylation
4
phosphorylation ser-552
4
ser-552 ampk/pi3k/akt
4
ampk/pi3k/akt pathway
4
pathway colorectal
4
cancer cells
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!